Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2‐Low Breast Cancer

Xiaoxiao Liu, Yuting Song, Lei Liu, Aaron Qi Zhang, Xin Xie, Bing Wei, Ping He, Chunying Zhuang, Juanjuan Li, Xi Yan, Tinglun Tian, Xiaorong Zhong, Jie Chen, Yan Cheng, Dan Zheng, Shibao Li, Hao Wang, Ting Luo · 2026

Read Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2‐Low Breast Cancer by Xiaoxiao Liu, Yuting Song, Lei Liu, Aaron Qi Zhang, Xin Xie, Bing Wei, Ping He, Chunying Zhuang, Juanjuan Li, Xi Yan, Tinglun Tian, Xiaorong Zhong, Jie Chen, Yan Cheng, Dan Zheng, Shibao Li, Hao Wang, Ting Luo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634177.txt.

Description

Breast cancers with low levels of a growth receptor lack targeted pre-surgery options, and a drug pair combining a targeted toxin carrier with an immune drug was tested in twenty patients. Xiaoxiao Liu and co-authors report that trial in this 2026 study, with deep molecular profiling to find who responds. Patients had stage two or three disease and got six cycles before surgery.

The main yardstick was whether any cancer remained in the removed tissue. Gene, protein, and immune profiling of samples searched for the traits that separated full responders from the rest. Immune features stood out in the response pattern, per the title. Small single-arm trials cannot prove the pair beats standard care, but their profiling can aim the larger trial that follows.

Catalog record

CREATORXiaoxiao Liu, Yuting Song, Lei Liu, Aaron Qi Zhang, Xin Xie, Bing Wei, Ping He, Chunying Zhuang, Juanjuan Li, Xi Yan, Tinglun Tian, Xiaorong Zhong, Jie Chen, Yan Cheng, Dan Zheng, Shibao Li, Hao Wang, Ting Luo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13634177

Browse the full library · About the Tower of Babel